09 Feb 2012
HOME
Pharma/CDC on Brain damage from vaccines, Fauci, Phages, Bioweapons manufacture
HHS.gov is Incompetent; BMJ calls fraud "crime.")
Official: CFIDS and MS-Lyme are the
same disease; Epstein-Barr
ELISA = arbitrary cutoff.
Disclaimer
1998, CIA Oilmen & Israelis plan to overthrow Saddam for the oil.
Bush/Gore Oil/War-(Oct,2000)
Bush's own explainer (Oct
2000):
Iraq Oil
Iraq was an oil-theft war.
ΣΛβ Sigma Alpha Beta (Self Ass-Biters Society)
The Weinstein Rule- Only 6 ton elephants may be diagnosed as elephants. Nevermind pesky details like SPECIFIC trunks, ears, feet, and skin...
Arthur Weinstein's VaLiDaTiOns. This guy is the methodological garbage generator of all time. The vaccine trials should never have been carried out until the blot-reading problem was resolved (3, below).
1) Western Blot for Lyme, according to the Weinstein VaLiDaTiOn CrItErIa:
Arthritis Rheum 1994 Aug;37(8):1206-11
Western blot band intensity analysis. Application to the diagnosis of Lyme arthritis.
Kowal K, Weinstein A.
New York Medical College, Valhalla 10595.
OBJECTIVE. To determine the usefulness of quantitative band-intensity analysis of Western blots for the diagnosis of Lyme arthritis. METHODS. IgG Western blots for antibodies to Borrelia burgdorferi were performed on sera from 39 patients with Lyme arthritis, 30 patients with syphilis, 50 patients with connective tissue diseases, and 10 healthy individuals. Band positions and band intensities were calculated using a computerized image analysis system. RESULTS. Lyme arthritis patients had more bands and higher-intensity bands than did non-Lyme patients. The presence of at least 2 bands of moderate to high intensity (> 40 optical units) or at least 5 bands of lower intensity (> 20 optical units) was over 90% sensitive and 100% specific for the diagnosis of Lyme arthritis. A 60-kd band was present in all Lyme arthritis patients. The presence of an 83-, 39-, 21-, or 18-kd band was highly specific for Lyme arthritis. CONCLUSION. Band intensity analysis increases the objectivity and accuracy of Western blot interpretation for the diagnosis of Lyme arthritis. PMID: 8053960 [PubMed - indexed for MEDLINE]This is the opposite of normal analytical methods development criteria. He is saying, that high antibody concentration is a valid way to diagnose Lyme disease. He is saying, the higher the concentration of antibodies, the more valid the test. The opposite is the normal course of analytical methods development. The criteria for the USP is Sensitivity (limit of detection, that means, "What is the LOWEST concentration of analyte that this method is good for?"), Specificity (refers to only the analyte in question), linearity (recovers analyte predictably in and out of matrix), Ruggedness (reproducible).
Lyme arthritis is a different disease than regular Lyme infection. Lyme arthritis happens in those genetically predisposed to reactive arthritis, and Steere, in Rahn and Evans (Lyme disease, Key Diseases Series, ACP, 1998), states that seropositve Lyme, or Lyme arthritis is part of the disease process.
In Steere and Dressler's prospective study, the Dressler/Steere IgG criteria found Steere's Lyme disease (LYMErix disease) 72% of the time, from those with arthritis, and not from those with Neuroborreliosis or the meningitis. The data was this: 39/54.
So, this Western Blot method is not even especially accurate for persons who have Steere's disease, or this Lyme arthritis. 72%. That means "back to the drawing board", in method development. This method just plain stinks, but it wasn't intended to be valid. The VACCINES were intended to be valid. They were not. They were just one molecule that is less often expressed in ticks feeding on ~37º C blood. OspC is upregulated at 37º C.
2) The Fibromyalgia Impact Questionaire, as "valid" for Lyme, according to the Weinstein VaLiDaTiOn CrItErIa:
Arthritis Care Res 1999 Feb;12(1):42-7
The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with post-Lyme disease syndrome.
Fallon J, Bujak DI, Guardino S, Weinstein A.
Leinhard School of Nursing, Pace University, Pleasantville, New York, USA.
OBJECTIVE: To determine the reliability and validity of a modified version of the Fibromyalgia Impact Questionnaire (FIQ) in evaluating patients with post-Lyme disease syndrome (PLDS). METHODS: In this cross-sectional analysis 13 PLDS, 18 fibromyalgia (FM), and 16 healthy controls (n = 47) completed a modified FIQ containing items to evaluate physical impairment, symptom severity, and global well-being. Comparisons between groups were done using analysis of variance with a significance level set at 0.05. RESULTS: PLDS patients demonstrated statistically significantly greater levels of impairment than controls in physical functioning, FIQ total score, global well-being, joint pain, fatigue, depression, ability to perform activities of daily living, and memory/concentration. FM patients demonstrated a statistically significantly greater level of impairment than the control group in all categories, and the scores were significantly higher than the PLDS group in the measurement of physical impairment, FIQ total score, muscle pain, and joint pain. Overall, the instrument possesses good reliability and validity, although adequacy of this instrument to measure impairment in the male PLDS population needs further elucidation. CONCLUSION: The results of this study suggest that the modified FIQ may be a useful tool in evaluating PLDS patients. ***The findings suggest that there may be some differences in the etiopathology of the symptoms experienced by PLDS and FM patients. *** PMID: 10513489 [PubMed - indexed for MEDLINE]
If the validation shows a difference, it's not valid, because it is not specific, Specificity being a requirement of an analytical method validation. The test can't test for something else, otherwise it is not a specific test.
Besides, these guys came up with plenty of markers of real disease on their own.
3) Weinstein was in charge of Data Integrity for the Connaught Vaccine Trial. 'Head of the Data Safety Monitoring. That would mean, he is reponsible for data monitoring, while Sigal ran this trial of Barbour's Connaught vaccine. The blots were not readable, according to Sigal:
fter the conclusion of the vaccine trials, one of the trial adminstrators, Lenny Sigal, published that the data, the results, the Western Blots used to qualify the vaccines, the MarDx blots, were actually unreadable:
http://www.journals.uchicago.edu/CID/journal/issues/v31n1/991200/991200.html
Detection of Multiple Reactive Protein Species by Immunoblotting after Recombinant Outer Surface Protein A Lyme Disease Vaccination Philip J. Molloy,1,2 Victor P. Berardi,2 David H. Persing,2,3,a and Leonard H. Sigal4 1Rheumatology Associates of Southeastern Massachusetts, Plymouth, and 2IMUGEN, Norwood, Massachusetts; 3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and 4Division of Rheumatology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick , Received 31 August 1999; revised 3 December 1999; electronically published 17 July 2000."...The challenge then will be to determine which bands result from recombinant OspA Lyme disease vaccination and which bands result from evolving B. burgdorferi infection. In the case of the FDA-approved immunoblot test kit, the identification of discrete bands at molecular weights >30 kDa is often unreliable or impossible because of the homogeneous staining in this area, compromising the ability of this test to diagnose Lyme disease in vaccinated study subjects. The manufacturer of the only currently FDA-approved (and released) recombinant OspA Lyme disease vaccine has suggested that vaccination does not interfere with serological evaluation of Lyme disease in vaccine recipients
a statement that is not supported by the data presented here."
Exactly how do you monitor data safety, when you don't know what you are looking at, and two years later, the leaders in Blot development, Persing, Molloy and Berardi (and Imugen and Steere and CT AG Station, Magnarelli, etc.) publish that after two YEARS, since the end of the vaccine trials, they still don't know what they are looking at?
What could have been Weinstein's conclusions? "Oh just never mind that overall darkness in the blot. It just means the blots are more valid, according to the Weinstein Validation Criteria..." ???
BLOT SMUDGING:
Figure 1. Results of Western blotting (MarBlot for detection of IgG antibody to Borrelia burgdorferi; MarDx, Carlsbad, CA) of serum specimens from 14 recipients of the recombinant outer surface protein A Lyme disease vaccine. Representative molecular weights (in kDa) are identified in the far left column. P, a positive control subject with PCR analysis positive Lyme arthritis; N, a negative control subject. Study subjects 1
Figure 2. Results of an alternate methodology for Western blotting (WB) of serum specimens from the same 14 study subjects in figure 1 who received the recombinant outer surface protein A (OspA) Lyme disease vaccine. Top portion of the figure represents WB with use of a conventional Borrelia burgdorferi strain (G39/40), and bottom portion represents WB with use of a B. burgdorferi strain lacking OspA expression. Representative molecular weights (in kDa) are identified in the far left column. P, a positive control with PCR analysis
See the link to the full text article, above.
I can't explain this. Neither can anyone else. Weinstein should have to explain it, since he proclaims himself an expert in bioassay.
Crooks publishing a procedure http://www.nccls.org/free/M34-A.PDF
======
Too stunningly un-brilliant to even comment:
Curr Opin Rheumatol 2002 Jul;14(4):383-7 Related Articles, Links
Lyme arthritis and post-Lyme disease syndrome.
Weinstein A, Britchkov M.
Section of Rheumatology, Washington Hospital Center, Washington, DC 20010, USA. arthur.weinstein@medstar.net
In the United States, intermittent or chronic mono- or oligoarthritis, particularly affecting the knee, is the most common manifestation of late Lyme disease (LD). [FALSE- It is the LEAST COMMON] Lyme arthritis (LA) can usually be prevented by early treatment of acute LD. However, the erythema migrans rash may go undetected in children and in the dark skin of African Americans, leading to delayed treatment and a relatively increased incidence in LA. Virtually all untreated patients with LA have high levels of serum immunoglobulin G antibodies, and sometimes low levels of immunoglobulin M antibodies, to Borrelia burgdorferi (Bb) by ELISA and Western blot. These responses may persist for many years after antibiotic treatment, and therefore, serologic results do not accurately distinguish between active or past infection. [FALSE, persisting and changing IgM means persisting infection.] Most patients with LA respond well to standard courses of antibiotic treatment, but a small percentage have persistent knee synovitis, in some cases possibly related to the triggering of intrasynovial autoimmunity.Other patients develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive difficulty during or soon after LD, which persists despite antibiotic treatment. Patients with this post-treatment, post-LD syndrome were recently studied in a placebo-controlled double-blind antibiotic trial. There was no evidence of Borrelial infection in these patients by culture or detection of Bb DNA in blood or spinal fluid. [False, the correct primers were not used.]
Furthermore, there was no difference in responsiveness of these patients to a 3-month course of antibiotic compared with placebo treatment. [False, the FIQ was not validated.] Thus, LA caused by active Bb infection, post-treatment LA with persistent knee synovitis and post-LD syndrome are distinct and distinguishable clinical entities.
Lyme arthritis vs.Neuroborreliosis. Imagine. And after only 27 years.
Rebuttal: http://www.ilads.org/stricker.htm
